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Abstract 
Purpose: Inhaled recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) has shown 
potential for the treatment of inflammatory lung conditions. Rapid inactivation of rSLPI 
by cathepsin L (Cat L) and rapid clearance from the lungs has limited clinical efficacy to-
date. Encapsulation of rSLPI within 1,2-Dioleoyl-sn-Glycero-3-[Phospho-L-
Serine]:Cholesterol liposomes (DOPS-rSLPI) protects rSLPI against Cat L inactivation in 
vitro. The aim of this study was to determine the effect of liposomes on rSLPI 
pharmacokinetics and activity in vitro and after local delivery to the airways in vivo. 
Methods: Transport of DOPS-rSLPI and free-rSLPI across a polarised air-liquid 
epithelial monolayer was measured. An asthma guinea pig model was administered either 
DOPS-rSLPI liposomes or free-rSLPI by intratracheal instillation. Results: Apparent 
permeability (Papp) of free-rSLPI was significantly higher at 4.9 x10
-6
cm/s than for 
DOPS-rSLPI, Papp of 2.05 x10
-7
cm/s. In vivo studies confirmed this result. Plasma rSLPI 
concentrations were highest in free-rSLPI treated animals compared with those treated 
with DOPS-rSLPI, there also appeared to be a trend for higher intracellular rSLPI content 
in animals dosed with DOPS-rSLPI compared to free-rSLPI. Eosinophil influx was 
recorded as a measure of inflammation. Pre-dosing with either free-rSLPI or DOPS-
rSLPI prevented inflammatory response to antigen challenge to levels comparable to 
control animals. Conclusion: Encapsulation of rSLPI in DOPS:Chol liposomes improves 
stability, reduces clearance and increases residence time in the lungs after local delivery. 
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Abbreviations 
AHR   Allergic hyperresponsiveness 
AIC   Air interface culture 
AMs   Alveolar macrophages 
Anti-NE  Anti-neutrophil elastase 
BAL   Bronchoalveolar lavage 
BALF   Bronchoalveolar lavage fluid 
Cat L   Cathepsin L 
Chol   Cholesterol 
EAR   Early allergic response 
Free-rSLPI  rSLPI alone 
DOPS   1,2-Dioleoyl-sn-Glycero-3-[Phospho-L-Serine] 
DOPS-rSLPI  rSLPI encapsulated in DOPS:Chol liposomes 
i.t.   Intratracheal instillation 
LAR   Late allergic response 
NE   Neutrophil elastase 
Ova   Ovalbumin 
Papp   Apparent permeability coefficient 
rSLPI   Recombinant secretory leukocyte protease inhibitor 
SLPI   Secretory leukocyte protease inhibitor 
TEER   Trans-epithelial electrical resistance 
 
 5 
Introduction  
 
Local drug delivery to the lungs is an effective means of treating a range of pulmonary 
diseases such as asthma, cystic fibrosis, bronchitis and emphysema [Suarez, 2000 #110]. 
SLPI is an 11.75kDa protein found intracellularly in the serous cells of submucosal 
tracheal and bronchial glands and in non-ciliated cells of the bronchus and bronchial 
epithelium. It is known to protect the lungs from excessive tissue damage caused by 
leukocyte proteases during inflammation (Yang et al., 2005). Its abundance in the upper 
respiratory tract suggests that the primary role of SLPI is to provide an anti-Neutrophil 
Elastase (anti-NE) shield for the tracheobronchial tree (Fryksmark et al., 1982, Mooren et 
al., 1983). SLPI has also been found to possess anti-bacterial, anti-viral and anti-
inflammatory activity including the ability to reduce nuclear factor-B (NF-B) 
activation intracellularly (Greene et al., 2004, Jin et al., 1997, Lentsch et al., 1999, 
McNeely et al., 1995, Taggart et al., 2002, Zhang et al., 1997). rSLPI is therefore a highly 
promising therapeutic for inflammatory lung disease.  
 
Delivery of rSLPI directly to the lungs by inhalation increases targeting to its site of 
action and has shown an increased half-life over intravenous administration (Bergenfeldt 
et al., 1990, Gast et al., 1990, Stolk et al., 1995). rSLPI’s therapeutic activity has been 
demonstrated previously in animal asthma models (Wright et al., 1999) and in human 
studies (McElvaney et al., 1993, McElvaney et al., 1992). The success of inhaled rSLPI 
therapy has been limited, however, by rapid clearance and extensive degradation by 
proteases, particularly cathepsins. In vivo human studies involving the delivery of rSLPI 
 6 
locally to the lung indicated that rSLPI does not accumulate on the respiratory surface 
and instead moves rapidly from the epithelial surface to the interstitium of the lung after 
inhalation (Vogelmeier et al., 1996). It therefore requires repeated dosages every 12 
hours in order to maintain therapeutic effectiveness (McElvaney et al., 1993).  
 
We have shown in an earlier study that encapsulation of rSLPI within1,2-Dioleoyl-sn-
Glycero-3-[Phospho-L-Serine]:Cholesterol (DOPS:Chol) liposomes protects rSLPI 
against Cat L inactivation in vitro (Gibbons et al., 2008). This delivery system is 
biocompatible and bioactive in vitro, is easily aerosolised and retains its protective 
properties post-nebulisation (Gibbons et al., 2008). Liposomes have advantages over 
other potential vehicles for lung targeting, including sustained release delivery of their 
cargo in the lungs, increased drug residence time in the lungs (Couvreur et al., 1991, 
McCullough and Juliano, 1979, Taylor et al., 1989), improved stability of the drug both 
in vitro and in vivo, biocompatibility (Niven and Schreier, 1990), local targeting 
providing increased potency and reduced toxicity (Gavalda et al., 2005a, Gavalda et al., 
2005b, Griffiths et al., 1999, Letsou et al., 1999). Also, the high loading capacity of 
liposomes and low excipient to drug ratio of lipid based carriers results in lower excipient 
accumulation in the lungs after repeated administration compared to polymer based 
carriers (Bhavane et al., 2003). The application of liposomes for the delivery of peptides 
or proteins to the lungs, however, has yet to be fully explored. 
 
In this paper the effect of liposome encapsulation on the pharmacokinetics and activity of 
rSLPI after local delivery to the airways was assessed in vitro and in vivo. In vitro 
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transport studies of free-rSLPI (rSLPI alone, non-encapsulated) and DOPS-rSLPI (rSLPI 
encapsulated in DOPS:Chol [7:3] liposomes) across Calu-3 airway epithelial monolayers 
grown under air interface culture (AIC) conditions were used to predict the effect of 
liposome encapsulation on rSLPI transport in vivo and to determine the value of this cell 
model for the prediction of formulation effects on protein transport rates in the lungs.  
 
An active model of asthma by Ova sensitisation in guinea pigs was used to determine if 
rSLPI encapsulation in DOPS-rSLPI liposomes has a significant effect on rSLPI’s 
activity and/or its pharmacokinetics after local administration to the lungs. Ovalbumin 
(Ova)-sensitised animals exposed to an Ova aerosol display the staggered inflammatory 
reactions associated with the asthma condition (Toward and Broadley, 2004). This model 
has previously been used to assess the effect of rSLPI delivered via inhalation (Wright et 
al., 1999). Asthma inflammation is associated with increased infiltration of inflammatory 
cells and the concurrent expression and release of inflammatory agents, which regulate 
processes of inflammation (Barnes, 2000, O'Byrne P and Postma, 1999). Of the 
inflammatory cell influx that occurs in the late allergic response (LAR) phase, 
eosinophils are of particular interest in asthma pathophysiology since they are the 
predominant inflammatory cell type detected in the airways of asthmatic patients (Frigas 
and Gleich, 1986). This asthma model was used to assess the degree to which free-rSLPI 
and DOPS-rSLPI regulated eosinophil influx in the LAR phase of the asthmatic response. 
Also, pharmacokinetic analysis was carried out by means of a single point assay of rSLPI 
in plasma, bronchoalveolar lavage fluid (BALF) and cell lysate samples.  
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Materials and Methods 
 
Materials 
Dulbecco’s Modified Eagle’s Medium (DMEM), Ham’s F12, Penicillin/Streptomycin 
(Bio-Science®); Foetal Calf Serum (FCS) (Sigma); Transwell plate (Costar); 
Trypsin/EDTA (1X) Liquid (Gibco); Calu-3 cells (American Type Culture Collection®, 
Manassas, VA, USA); 1,2- Cholesterol and 1,2-Dioleoyl-sn-Glycero-3-[Phospho-L-
Serine] (DOPS) (Avanti Polar–Lipids® Inc.); Recombinant human rSLPI was a gift from 
Amgen® (Thousand Oaks, CA, USA); Human Sputum Leukocyte Elastase (Elastin 
Products Company®, Missouri, USA); Rabbit anti-SLPI polyclonal IgG and goat anti-
rabbit IgG-HRP antibody (Santa Cruz Biotechnology® Inc.); I-block (Applied 
Biosystems); Super-Signal West Pico Chemiluminescent S (Medical Supply Company®, 
Dublin, Ireland); Human Neutrophil Elastase (NE) (Elastin Products Co.); Vydac narrow 
bore C18 column (#218TP5205), (Vydac, Hesperia, CA); Male Hartley guinea pigs 
(Hilltop Lab Animals Inc. Hilltop Drive, Scottdale, PA); IA-1C MicroSprayer (Penn-
Century Inc, Philadelphia, PA); Harvard Rodent Ventilator, Model 683 (Harvard 
Apparatus, Suthnatick, MA), Human rSLPI ELISA (Quantikine), Cathepsin L, N-
(Methoxysuccinyl)-Ala-Ala-Pro-Val 4-nitroanilide and all other reagents were obtained 
from Sigma-Aldrich® (Tallaght, Dublin, Ireland).  
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Methods 
Liposome preparation and characterisation 
Dioleoylphosphatidylserine:Cholesterol (DOPS:Chol) liposomes were prepared by the 
conventional thin film hydration procedure. Briefly DOPS was mixed with Cholesterol at 
a ratio of 7:3 and dissolved in Chloroform:Methanol (2:1). The 7:3 ratio for DOPS:Chol 
was based on previously published studies (Gibbons et al, 2008) wherein we determined 
this lipid mix provided adequate liposomal stability for our application. Solvent was 
removed by evaporation using a rotary evaporator at approximately 100rpm. rSLPI was 
incorporated into the formulation in a rehydrating buffer (Phosphate Buffered Saline 
(PBS), pH 7.4). 6ml batches of DOPS-rSLPI were prepared for in vivo studies composed 
of DOPS (5.67mg/ml), Chol (1.145mg/ml) and rSLPI (0.33mg/ml).  Size reduction of the 
liposome suspension was achieved by extrusion using a mini-extruder (Avanti Polar-
Lipids Inc.) through 200nm pore size polycarbonate membranes. Non-encapsulated 
protein was removed by centrifugation at 45 000 rpm at 4ºC for 40 minutes. The 
supernatant was removed and the pellet washed with PBS and re-centrifuged. This step 
was repeated for a further two washes.  When required 1,2-Dioleoyl-sn-Glycero-3-
Phosphocholine:Cholesterol (DOPC:Chol) 7:3 liposomes were prepared by the 
conventional thin film hydration procedure as described above. For high content analysis,   
L-α-Phosphatidylethanolamine-N-(lissamine rhodamine B sulfonyl) was added to 
fluorescently label liposome preparations. 
 
The size distribution of the liposomes was determined by dynamic light scattering (DLS) 
(HPPS®, Malvern Instruments) and zeta potential of the liposomes was analysed using 
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laser Doppler electrophoresis (LDE) (Zetasizer Nano ZS®, Malvern Instruments). The 
encapsulation efficiency of rSLPI in DOPS:Chol liposomes was determined by reverse 
phase-HPLC (RP-HPLC). Briefly, liposomes were disrupted via 0.5% Triton X and 
loaded onto a Vydac narrow bore C18 column (#218TP5205, Vydac®, Hesperia, CA) for 
RP-HPLC analysis using a slightly modified procedure previously described (Gibbons et 
al., 2008). Gradient elution occurred over 40 minutes using a mobile phase of water and 
acetonitrile with 0.1% trifluoroacetic acid and rSLPI. Area under the curve was analysed 
at 214nm. The supernatant samples (non-encapsulated rSLPI) were also analysed by RP-
HPLC. %EE was defined as the rSLPI encapsulated in liposomes as a percentage of 
loading dose. The Stewart assay was used to determine the concentration of phospholipid 
present in the liposomal formulations. Briefly 2ml chloroform and 2ml ferrothiocyanate 
reagent and 0.1ml of liposome sample were vortexed vigorously for 1 minute. The 
resultant mixture was centrifuged at 1,000rpm for 5min and the lower chloroform layer 
removed by glass pipette and measured at 485nm. Based on a standard curve for the 
appropriate lipid, the concentration of phospholipid present in the sample was calculated. 
 
rSLPI stability and in vitro activity 
Western blot analysis was carried out to ensure that the molecular weight of rSLPI had 
not been altered during the formulation steps. Samples and standards containing 125ng 
rSLPI were electrophoresed on 15% polyacrylamide gel and blotted onto nitrocellulose. 
After blocking in I-block®, rSLPI was detected using affinity purified rabbit anti-SLPI 
polyclonal IgG (1:1000 in I-block) for 1h followed by incubation with goat anti-rabbit 
 11 
IgG-HRP antibody (1:7500) for 1h. Development was carried out using SuperSignal 
West Pico® chemiluminescent substrate kit (Taggart et al., 2001). 
 
Activity of rSLPI was assayed by measuring its inhibition of human neutrophil elastase 
(NE) activity on the substrate N-methoxy-succinyl-Pro-Ala-Ala-Val-p-nitroanilide. rSLPI 
was incubated with NE at room temperature for 5min. Upon addition of the substrate, the 
change in absorbance (Abs) at 405nm was measured from T0 to T5min (McElvaney et al., 
1992).  
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 Cell Culture  
The Calu-3 cell line is a bronchial epithelial cell line isolated from an adenocarcinoma of 
the lung, as established by Fogh et al (Fogh et al., 1977). Cells were grown in 150cm
2
 
flasks at 37ºC in a humidified atmosphere containing 5% CO2 with media replenished 
approximately every second day. Media consisted of a 1:1 mixture of Ham's F12:DMEM 
containing 10% foetal bovine serum (FBS), 100μg/ml penicillin G and 100μg/ml 
streptomycin sulphate. For transport studies 0.5 x10
6
 cells/cm
2
 cells were seeded onto 
filter supports (12 well Transwell plate, Costar®) and grown at an air-liquid interface. 
 
A human monocyte-like cell line (THP-1) was cultured in T25, vented flasks. Culture 
medium was free from antibiotics and consisted of RPMI-1640 with 10% Foetal bovine 
serum. Cells were seeded at a density of 2.5 x 10^
5
 cells / ml and allowed to grow to a 
confluence of 1 x 10^
6
 cells / ml before splitting or plating the cells. Cells grew in 
suspension and were centrifuged at 200xg for 10 minutes when changing medium or 
seeding cells. To differentiate cells into adherent macrophage like cells 100nM PMA was 
used for 72 hours at 37°C / 5% CO2. 
 
Measurement of Trans-epithelial Electrical Resistance (TEER) 
TEER values were measured using the EVOM voltohmeter (World Precision 
Instruments, USA) fitted with STX ‘chopstick’ electrodes. TEER was expressed as 
resistance (Ω) by unit area (cm2). Readings above 700Ω.cm2 were considered 
representative of a confluent monolayer. Readings were taken prior to addition of 
supplemental media. The resistance of unseeded wells was measured as the control 
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resistance. TEER values were measured before addition of free-rSLPI (10µg/ml) and 
DOPS-rSLPI (10µg rSLPI per ml) and at defined intervals during the incubation time 
period of 0, 2, 6, 24 and 30 hours. The TEER for each well was calculated using the 
following equation: T Cell Monolayer = (T Test – T Control),  where  
T Cell Monolayer = Resistance of the cell layer alone (Ω.cm
2
),  
T Test = Resistance of the cell layer and filter (Ω.cm
2
)  
T Control = Resistance of the filter alone (Ω.cm
2
). 
 
Transport studies of free-rSLPI and DOPS-rSLPI Across a Calu-3 Monolayer 
rSLPI transport across airway mucosa was assessed using Calu-3 monolayers, cultured as 
described, 8 days after seeding. rSLPI (10µg rSLPI in 100µl Krebs® solution) was added 
to each Transwell® containing confluent Calu-3 monolayers as either free-rSLPI or 
rSLPI encapsulated in DOPS-rSLPI liposomes. Samples were removed from the 
basolateral chamber and replaced with an equivalent volume of Krebs® solution at 5, 30, 
60, 120, 240 and 420 minutes and apical samples were taken at 420 minutes. Basolateral 
and apical samples were assayed for rSLPI concentration by ELISA (Quantikine®). 
Apparent permeability rate (Papp) was used to assess the transport of rSLPI across the 
cell monolayer. Results were expressed as the apparent permeability coefficient (Papp) of 
rSLPI. Papp is calculated using the following equation: 
Papp  =  dQ/dt  X  1/A.C0 
Where, 
dQ/dt = Rate of appearance of mass in the basolateral chamber (mg/s) 
A = Surface area of the filter (cm
2
), which is 1.12cm
2
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C0 = Initial concentration of drug in the apical chamber (mg/ml). 
 
High content analysis of liposome uptake into THP-1 cells 
To quantify the number of liposomes per THP-1 cell a high-content screening system was 
developed with an INCell 1000 lyser (GE). Various size ranges were evaluated in 48-well 
plates with 0.5ml of PMA treated THP-1 cells at a density of 1x10^5 cells / ml per well. 
Cells were differentiated with 100mM PMA for 72 hours, followed by replacement with 
fresh media and were incubated for 2 hours with rhodamine-labelled liposomes of 
different sizes, washed and analysed at 37°C. Cells were then fixed in 4% 
paraformaldehyde and stained for F-actin with 200μl of Phalloidin-TRITC (5µg/ml) and 
for nucleus using 100μl of Hoechst (10µg/ml). Dual object analysis was carried out on 
the INCell 1000 to quantify the rate of cell uptake. Cells were identified as objects with 
both a defined radius of cell shape and also a minimum surface area of the nucleus. 
Positive objects for both these characteristics were then scanned for liposomes of a 
defined size range. Images were analysed using the dual area object analysis algorithm 
(GE) to quantify the number of liposomes uptake (Table 1).  The number of liposomes 
per cell is quantified by the software first identifying cells; it does so by using two 
organelle markers, the nucleus and the cytoplasm. In this study the nucleus was 
fluorescently labelled with Hoechst (blue) 360nm / 460nm (nucleus), and with 
Phalloidin-FITC (green) 535nm / 620nm (cytoplasm). A threshold for area intensity for 
the respective dyes is employed in the identification of defined cells. Once identified, the 
software can use a size exclusion algorithm to count the number of fluorescently- labelled 
particles within the cell; the software can be programmed to count only those fluorescent 
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particles within a defined size range.  The software will only count particles that are 
within the defined region, i.e. within the cell, co-localised with the intracellular 
cytoplasmic phalloidin stain.  
 
Guinea Pig Asthma Model  
In vivo studies involving the guinea pig asthma model were carried out according to an 
IACUC approved protocol (Web ID 8135). Male Hartley guinea pigs (400-600g) were 
actively sensitized by intra-peritoneal (i.p.) injection of 0.1mg ovalbumin [Ova] in 100mg 
aluminium hydroxide gel (Smith and Broadley, 2007, Wright et al., 1999). Control 
animals, which would not be sensitised to Ova, were given a sterile saline i.p. injection 
instead of ovalbumin. Guinea pigs were anaesthetised using an anaesthetic cocktail 
comprised of ketamine (50mg/kg) and xylazine (5mg/kg) delivered subcutaneously (s.c.). 
When required for i.t. instillation, light anaesthesia was used to ensure that the animals 
did not suffer respiratory depression.  
 
A previous study by Wright et al demonstrated the ability of a single 5mg/kg dose of 
rSLPI to inhibit airway hyperresponsiveness (AHR) when administered up to 48 hours 
prior to Ova challenge (Wright et al., 1999). In another study carried out by the same 
group, rSLPI was administered over four days as once daily doses of 3mg with the final 
dose administered 30 minutes prior to antigen challenge providing 48 and 100% 
inhibition of peak early and late phase bronchoconstriction respectively. In our study, a 
single dose containing 2.5mg rSLPI per kg (or the equivalent volume of PBS/ DOPS-
Blank) was administered intratracheally and guinea pigs were challenged 24 hours later 
with Ova. We also studied a three-day prophylactic dosing regime where guinea pigs 
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received once daily doses of 1mg rSLPI/kg body weight. For all groups examined, guinea 
pigs were sensitised with 100µg Ova by i.p. injection, or saline injected for control 
animals on day one. Fourteen days later the animals were dosed by intratracheal 
instillation. An IA-1C MicroSprayer® (Penn-Century Inc, Philadelphia, PA) was used to 
deliver a plume of liquid aerosol directly to the lungs of the guinea pigs via an 
intratracheal catheter. Two 1ml boluses of air were administered through the 
MicroSprayer® cannula directly after each instillation. This ensured that the air passage 
was clear for ventilation. After each dose the animals were held in an upright position on 
a heating pad for 10 minutes before laying them at an angle in the prone position until 
fully recovered from the anaesthetic. Intratracheal instillation of therapeutic or blank 
samples were administered according to one of the following dosage regimes:  
 
i) Single Prophylacticly Dosed Guinea Pigs 
On day 14 of the study, guinea pigs were administered one dose of the following by i.t. 
instillation: i) free-rSLPI (2.5mg rSLPI/kg), ii) DOPS-rSLPI (2.5mg rSLPI/kg), iii) 
DOPS-Blank or iv) PBS (pH 7.4). On day 15 of the study, guinea pigs were Ova 
challenged by intratracheal instillation, followed 24 hours later (day 16 of the study) by 
euthanasia and collection of plasma, BALF and cell samples for ELISA analysis. A late 
allergic response (LAR) to Ova challenge was also examined using cell differentiation 
analysis to measure the influx of inflammatory cells into the airways as symptomatic of 
the asthmatic response to Ova. 
 
ii) Three-Day Prophylacticly Dosed Guinea Pigs 
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On day 14 of the study, guinea pigs were initiated on a three-day prophylactic dosage 
regime, whereby animals received once-daily i.t. instillations of either  i) rSLPI (1mg/kg 
body weight), ii) DOPS-rSLPI (1mg rSLPI per kg), iii) DOPS-Blank or iv) PBS (pH 7.4) 
for three days. On the 3rd day of dosing (day 16 of the study), animals were euthanised 2 
hours after the final dose and plasma, and BAL cell samples were collected for ELISA 
analysis. Collection of BALF proved impossible in this dosage regime due to 
pneumothorax. BAL cell samples could still be collected and assayed despite 
pneumothorax, as the concentration assayed was normalised to that in one million cells, 
and therefore not reliant on BAL volume. 
 
rSLPI distribution 
Plasma samples were obtained by cardiac puncture after the animal was euthanised. 7ml 
was withdrawn from the cardiac puncture and 100µl Heparin added. The sample was 
placed at an angle for 5 minutes then mixed by stirring and centrifuged at 12,000 rpm for 
10 minutes. The supernatant was removed and stored at -80ºC. Samples were thawed and 
diluted a minimum of 20 fold with Calibrator Diluent RD5T from the SLPI ELISA kit 
(Human SLPI ELISA, Quantikine®, R&D Systems). 
 
Bronchoalveolar lavage (BAL) was carried out to retrieve airway cells and BALF. 
Directly after euthanasia of the animal, 5ml PBS (pH 7.4) was passed into the lungs using 
a 5ml syringe and withdrawn 1 minute later. The lungs were flushed three times with 5ml 
PBS.  BALF was pooled and centrifuged immediately at 500 relative centrifugal force 
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(r.c.f.) for 5 minutes. The BALF supernatant was removed and stored at -80ºC until 
required for ELISA analysis (Quantikine®). 
 
Cell pellets from BAL were made up to a volume of 1ml with PBS. The total cell count 
(cells/ml) present was calculated 1:1 with Trypan blue using a Neubauer haemocytometer 
(Fisher Scientific International Inc.). For the intracellular assay of rSLPI, cell pellets were 
thawed and centrifuged at 1,100rpm to obtain a cell lysate and to remove cellular debris. 
Dilutions of the cell lysate were made in Calibrator Diluent RD5T. Concentrations 
assayed in the cell lysate samples were normalised to the amount present in one million 
cells. rSLPI assay was carried out using the Human SLPI ELISA kit (Quantikine®). 
 
Inflammatory Cell Influx 
Eosinophils are the predominant inflammatory cell type in asthmatic airways and as such 
were a useful marker in this study for airway inflammation in the late phase asthmatic 
response and airway hyperresponsiveness that occurs between 6 and 24 hours after Ova 
challenge (Danahay and Broadley, 1997, Frigas and Gleich, 1986). Inflammatory cell 
influx was tested in guinea pigs where a single prophylactic dose of test or blank sample 
was administered and the influx of eosinophils into the lungs 24 hours after Ova 
challenge assessed as a marker of inflammation. 
 
An aliquot of the cell pellet was spun down on a microscope coverslip at 1,100rpm for 7 
minutes. A minimum of 500 cells was counted and the proportion of eosinophils, 
monocytes, neutrophils and basophils present was calculated (Smith and Broadley, 2007, 
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Smith and Johnson, 2005). The cells were fixed with acetic alcohol (3% acetic acid in 
95% methanol) for 1 minute before rinsing the fixative off gently with distilled water. 
The slides were placed on a rack and covered with 1ml of Leishman’s stain (0.15%w/v in 
100% methanol), for approximately 20 seconds. 2ml of a pH 6.8 buffer was added to the 
coverslip and the two solutions were mixed by tipping the coverslip up and down for 7 
minutes. This was then removed by rinsing with distilled water followed by treating of 
the coverslip with buffer (pH 6.8) for a further 2 minutes. The buffer was rinsed off with 
distilled water and the coverslip allowed to dry and mounted on a microscope slide. The 
slides were examined and cells counted using a light microscope using a 100 
magnification lens. Neutrophils, eosinophils, monocytes and basophils were counted if 
present. Results were expressed as the percentage eosinophil cells present as a percentage 
of the total cell count.  
 
Statistical Analysis  
Results were expressed as mean ± standard deviation. Where appropriate the unpaired t-
test was used to determine the significance of results. A one-way analysis of variance 
(ANOVA) was used to determine the significance of results obtained for percentage 
inflammatory cell influx. In all cases, a probability value of less than 0.05 was considered 
to be significant. 
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Results 
Liposome encapsulation of rSLPI 
rSLPI was encapsulated in DOPS:Chol liposomes with an average encapsulation 
efficiency of 74.1 ±2.97%. Post-extrusion, these liposomal systems were found to be 
153.6 ±2.47nm in size and had a ζ-potential of -58.8 ± 1.46 mV”. The stability of rSLPI 
after encapsulation was confirmed by RP-HPLC and western blot analysis and the 
retention of anti-protease activity was assessed by its ability to inhibit neutrophil elastase 
(NE) activity in vitro. No degradation of rSLPI was evident with encapsulated rSLPI 
retaining 92.6 ±10.1% of its anti-NE activity compared to rSLPI prior to encapsulation. 
In vitro release studies using a dialysis method indicated that the liposomes provided a 
degree of controlled release.  73% of free rSLPI was released within 4 hours (240mins), 
with a three-fold reduction in the amount of rSLPI released from the rSLPI-liposomes at 
each time point sampled compared with the free rSLPI controls. 
 
In vitro rSLPI Transport Across Calu-3 Airway Epithelial Cell Monolayers 
In vitro transport studies were conducted to assess the effect of liposome encapsulation 
on rSLPI transport across an air liquid interface using Calu-3 airway epithelial cell 
monolayers. This was carried out as a preliminary in vitro study to predict the rate of 
systemic absorption of free-rSLPI compared to rSLPI encapsulated in DOPS-rSLPI in 
vivo. Firstly a TEER analysis study was carried out to assess the effect of free-rSLPI and 
DOPS-rSLPI incubation on Calu-3 cell monolayer integrity. 
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TEER values were recorded over a 30 hour incubation of Calu-3 cells with free-rSLPI 
and DOPS-rSLPI. TEER values were taken at defined time points over the 30 hour 
incubation. There was no significant difference in the integrity of the monolayer between 
control cells (incubated alone) and cells incubated with free-rSLPI or DOPS-rSLPI.  
 
Cells were incubated with free-rSLPI (10µg rSLPI/ml) and DOPS-rSLPI (10µg 
rSLPI/ml) for 4 hours. TEER values were taken before and after completion of the study 
to ensure that the cell monolayer remained uncompromised throughout the study. 
Samples were removed from transwells at defined time points. ELISA (Quantikine, R&D 
Systems®) was used to quantify rSLPI concentration in the samples removed. The 
calculated apparent permeability (Papp) for free-rSLPI was 4.9x10
-6
cm/s while Papp for 
DOPS-rSLPI was calculated to be 2.0x10
-7
cm/s. Transport across the monolayer 
therefore occurred at a faster rate for free-rSLPI than rSLPI encapsulated in DOPS-rSLPI 
liposomes (Figure 1). 
 
In vivo study 
An asthma guinea pig model was used to fully elucidate the effect of encapsulation on the 
anti-inflammatory activity of rSLPI. The study was carried out as outlined previously. 
Two weeks after the initial ovalbumin challenge animals were anaesthetised and dosed by 
intratracheal (i.t.) instillation using either a single prophylactic dose or a three-day 
prophylactic dose regime.   
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In the single prophylactic dose regime, animals were administered either 2.5mg/kg free-
rSLPI or rSLPI encapsulated in liposomes (DOPS-rSLPI). Control animals were 
administered an equivalent volume of blank liposomes (DOPS-Blank) or phosphate 
buffered saline (pH 7.4) in place of the test substance. Plasma and BALF samples were 
collected 48 hours after the single prophylactic dose (day 16). All biological fluid 
samples were analysed using a highly sensitive ELISA kit that can detect rSLPI in 
picogram concentrations.  
 
Plasma samples from the study animals were obtained by cardiac puncture. Plasma levels 
of rSLPI in animals assayed 48 hours after the single prophylactic dose (2.5mg rSLPI/kg 
by i.t.) showed significantly higher plasma concentrations for guinea pigs dosed with 
free-rSLPI of 12.3 ±3.07ng/ml compared to those dosed with DOPS-rSLPI (0.52 
±0.85ng/ml) (p < 0.001) (Figure 2). 
 
rSLPI was still detectable in bronchoalveolar lavage fluid (BALF) 48 hours post-
instillation for animals treated with free-rSLPI (single i.t. dose, 2.5mg rSLPI/kg). 
Significantly higher concentrations of rSLPI were observed in the BALF for free-rSLPI 
treated animals of 7.58 ±1.52ng rSLPI, compared to BALF concentrations assayed in 
animals treated with DOPS-rSLPI (3.22 ±1.73ng rSLPI) (p < 0.02) (Figure 3).  
 
Cell lysates of BALF cells taken from animals 48 hours after the single prophylactic dose 
were also assayed for rSLPI concentration. Although not statistically significant, there 
appeared to be a trend towards higher rSLPI intracellular concentrations in animals 
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treated with DOPS-rSLPI 48 hours after dosing, with intracellular rSLPI concentrations 
of 0.267 ±0.20µg/10
6
cells compared to 0.10 ±0.029µg/10
6
cells for those treated with 
free-rSLPI (Figure 4). 
 
In the three-day prophylacticly dosed regime, guinea pigs were administered once daily 
i.t. instillations for three days of either 1mg/kg free-rSLPI or rSLPI encapsulated in 
liposomes (DOPS-rSLPI). Control animals were administered an equivalent volume of 
blank liposomes (DOPS-Blank) or phosphate buffered saline (pH 7.4) in place of the test 
substance. On the 3rd day of dosing (day 16 of the study), animals were euthanised 2 
hours after the third and final dose. Plasma, and cell samples were assayed for rSLPI 
content using ELISA analysis. 
 
Plasma samples from the three-day prophylacticly dosed animals were obtained by 
cardiac puncture. Plasma levels of rSLPI in animals assayed 2 hours after final dosing 
showed a significantly higher plasma rSLPI concentration for animals dosed with free 
rSLPI (1mg/kg; n=2) of 418.3 ±63.71ng/ml rSLPI compared to 30.1 ±3.66ng/ml rSLPI 
for animals dosed with DOPS-rSLPI (1mg rSLPI/kg; n=2) (p <0.02) suggesting that 
rSLPI from the DOPS-rSLPI liposome formulation is not cleared as rapidly to the 
systemic circulation as free-rSLPI (Controls [DOPS-Empty or PBS] n=6).  
 
Cell lysates of BALF cells taken from these animals 2 hours after dosing (1mg rSLPI/kg 
once daily for three days) were also assayed for rSLPI concentration and demonstrated 
significantly higher rSLPI concentrations in the cell lysate of animals treated with DOPS-
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rSLPI at 5.15 ±0.086µg/10
6
cells (n=2) compared to animals treated with free rSLPI (0.22 
± 0.098µg/10
6
cells; n=2) (p <0.0005). Intracellular rSLPI concentration for animals 
treated with free rSLPI and DOPS-rSLPI were statistically higher than for control 
animals (Controls [DOPS-Empty or PBS] n=9). 
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Inflammatory Cell Infiltration 
Inflammatory cell infiltration into the airways, specifically eosinophil influx, is indicative 
of local lung inflammation and is known to occur between 6-24 hours after early allergic 
response (EAR). The percentage cell type present in the airways was expressed as a 
percentage of total cells present. A minimum of 500 cells was counted after cell 
differentiation using Leishman’s stain (Figure 5 & 6). Control animals that received Ova 
challenge only, displayed a significantly higher level of eosinophil influx compared to all 
other groups of animals (p <0.001) (Figure 6). A significantly lower level of eosinophils 
was observed in the BAL of animals prophylacticly treated with a single prophylactic 
dose of free-rSLPI and DOPS-rSLPI. The eosinophil levels in these treated animals were 
statistically similar to that for unchallenged animals (p>0.05) (Figure 6). There was no 
statistical difference in neutrophil count between the animal groups.  
 
 
After euthanasia of guinea pigs, various organs were assessed for the incidence of 
toxicity induced by free-rSLPI or DOPS-rSLPI treatment. The liver, gall bladder and 
lungs were all assessed for toxicity. No abnormalities, which would suggest toxicity, 
were observed in the organs of any test group.  
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Discussion 
 
Our previous work demonstrated highly efficient encapsulation of rSLPI within 1,2-
Dioleoyl-sn-Glycero-3-[Phospho-L-Serine]:Cholesterol (DOPS:Chol) liposomes, which 
protect rSLPI against Cat L inactivation in vitro (Gibbons et al., 2008). In this paper the 
effect of liposome encapsulation on the pharmacokinetics and activity of rSLPI after local 
delivery to the airways was assessed in vitro and in vivo.  
 
An in vitro transport study was conducted using Calu-3 airway epithelial cells grown to 
confluency at an air-liquid interface to form intact monolayers capable of mimicking the 
mucosal cell layer in the bronchial region of the airways (Shen et al., 1994). The Calu-3 
cells line  has previously been used as a means of potentially predicting the transport of 
materials across the airway epithelium in vivo (Fiegel et al., 2003, Foster et al., 2001). In 
our study a significant difference was observed in apparent permeabilities of free-rSLPI 
and DOPS-rSLPI across the Calu-3 monolayer indicating that transport occurred at a 
much faster rate for free-rSLPI compared to that for rSLPI encapsulated in DOPS-rSLPI 
liposomes (Figure 1). This rapid transport of free-rSLPI across the airway epithelial cells 
could explain the rapid clearance of the inhaled protein previously seen in in vivo studies 
(McElvaney et al., 1993, Vogelmeier et al., 1996). The encapsulation of rSLPI within this 
liposome carrier therefore appears to retard transport across the epithelium, which could 
signify increased rSLPI residence time within the lungs when encapsulated in DOPS-
rSLPI liposomes compared to free-rSLPI.  
 
 28 
To determine the effect that encapsulation of rSLPI in liposomes has on its in vivo 
pharmacodynamics, in vivo studies were carried out using a guinea pig asthma model. In 
vivo studies using rSLPI therapy have previously been carried out in sheep, mouse and 
guinea pig asthmatic models (Wright et al., 1999). In studies by Wright et al using the 
sheep model, it was observed that the prophylactic dosage regime of 3mg daily for four 
days provided inhibitory activity equivalent to that achieved by a single 100mg aerosol 
dose of rSLPI. Using a different animal model to test the effect of rSLPI on 
hyperresponsiveness, Wright et al administered intratracheal doses of rSLPI (1mg/kg) to 
guinea pigs at daily intervals for three days with the final dose administered one hour 
before antigen challenge. It was observed that this inhibited the development of 
hyperresponsiveness induced by histamine bronchoprovocation with a lower ED50 
<0.05mg/kg compared to a single dose of rSLPI given one hour before antigen challenge 
displayed an ED50 of 0.56mg/kg. In a murine model treated with rSLPI 30 minutes prior 
to antigen challenge it was found that rSLPI treatment inhibited eosinophil, lymphocyte 
and neutrophil influx decreased by almost 100%.  
 
In our study, Ova-sensitised guinea pigs were dosed by intratracheal (i.t.) instillation with 
either a single prophylactic dose of free-rSLPI (2.5mg rSLPI/kg), or DOPS-rSLPI 
liposomes (2.5mg rSLPI/kg) where samples were collected from guinea pigs 48 hours 
after euthanasia, or, a three-day prophylactic dose regime of once daily doses of either 
free-rSLPI (1mg rSLPI/kg), or DOPS-rSLPI (1mg rSLPI/kg) where samples were 
collected 2 hours after the final dose. The high rSLPI concentration seen in plasma 
samples at 2 hours post i.t. instillation of free-rSLPI indicates that rSLPI is rapidly 
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cleared from the lungs into the systemic circulation while DOPS-rSLPI is not cleared so 
readily and may remain in the lungs. A significantly higher concentration of rSLPI was 
also observed in the plasma of animals treated with a single dose of free-rSLPI compared 
to animals treated with DOPS-rSLPI 48 hours after treatment suggesting the retention of 
liposome-encapsulated rSLPI within the lungs and corroborates the high apparent 
permeability of free-rSLPI observed in the in vitro transport study.  
 
Other studies investigating the clearance of rSLPI from the lungs using various different 
in vivo models (rats, sheep and human) have also demonstrated that free-rSLPI is rapidly 
cleared from the lungs to the extent that a once daily dose would not be sufficient to 
maintain therapeutic rSLPI levels within the lungs (Gast et al., 1990, McElvaney et al., 
1993, Vogelmeier et al., 1990). In a study where rSLPI was nebulised into the lungs of 
sheep, Vogelmeier et al found the half-life of rSLPI in the epithelial lining fluid of the 
lungs to be 12 hours (Vogelmeier et al., 1990). When rSLPI was administered 
intratracheally to the lungs it disappeared from the lungs with a half-life of 4 to 5 hours. 
In that study rSLPI was absorbed systemically from the lungs with a resulting maximal 
plasma level of about 2µg/ml approximately one to two hours after administration (Gast 
et al., 1990) which also corroborates the data found in our study. Many studies have 
documented the ability of liposomes to provide sustained release for their encapsulated 
material (McCullough and Juliano, 1979, Murry and Blaney, 2000, Taylor et al., 1989). 
The trend for rapid systemic clearance of free-rSLPI relative to DOPS-rSLPI treated 
animals up to 48 hours after administration indicates that encapsulating rSLPI in the 
liposome carrier promotes a longer residence time within the lungs. 
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Despite the rapid absorption of free-rSLPI from the lungs into the systemic circulation 
(Figure 2) 2 hours and 48 hours after administration, free-rSLPI was still detectable in the 
BALF in trace concentrations (approximately 8ng/ml) (Figure 3). This residual presence 
of rSLPI in the BALF may be due to its biphasic clearance from the lungs. In biphasic 
clearance, materials that deposit in certain regions of the lungs are rapidly cleared, while 
those that deposit in other areas, typically non-ciliated regions, are cleared at a slower 
rate (Smith et al., 1989, Stolk et al., 1995).  
 
The relative lack of DOPS-rSLPI in the BALF 48 hours after administration (Figure 3) 
leads to the following question; if rSLPI was not in the systemic circulation nor in the 
BALF of DOPS-rSLPI treated animals, then where was it? Intracellular rSLPI 
concentrations in BAL cells were assayed. BAL cells were collected from the three-day 
prophylacticly dosed guinea pigs 2 hours after the final dose and assayed for rSLPI 
concentration. An extremely significant increase in intracellular rSLPI concentrations 
was observed for DOPS-rSLPI treated animals versus free-rSLPI treated animals 
(p<0.05). BAL cells were also collected from animals 48 hours after a single prophylactic 
dose, and although not statistically significant, there appeared to be a trend for higher 
intracellular rSLPI concentrations in animals treated with DOPS-rSLPI compared to 
those treated with free-rSLPI 48 hours post-administration (Figure 4). The variability 
between samples in the single dose study was almost certainly due to the 48 hour gap 
between dosing and sampling. The majority of cells present in the BALF of free-rSLPI 
and DOPS-rSLPI treated animals were monocytes (Figure 5) and it can therefore be 
postulated that a large proportion of the encapsulated DOPS-rSLPI was targeted to 
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monocytes in the lungs. Uptake facilitated by the DOPS liposomes that was indicated by 
our in vivo data (Fig 4a) was confirmed by studies to assess the impact of liposome 
composition on uptake by monocytes in vitro (Fig 4b). These studies confirmed a 
significant increase in monocyte uptake of DOPS liposomes compared to DOPC 
liposomes at a range of concentrations. Qualitative and quantitative data from HCA 
studies confirmed that DOPS liposomes were capable of efficiently targeting monocytes, 
a property that was independent of size (Fig 4b). This technique allowed individual 
liposomes per cell to be counted, thereby removing the subjectivity of microscopy 
studies. 
 
It is already known that phosphatidylserine (PS) lipids enhance macrophage uptake (Chiu 
et al., 2001, Martin et al., 1995) and PS expression on the surface of cells has long been 
recognised in cell biology to signal apoptosis and to trigger the phagocytosis of apoptotic 
cells by macrophages (Bratton and Henson, 2008, Fadok et al., 1992, Martin et al., 1995). 
Further studies have reported extensive uptake of DOPS liposomes by macrophages and 
demonstrated enhanced alveolar macrophage uptake of negatively charged liposomes 
deposited in the lungs of mice (de Haan et al., 1996). Along with its extracellular 
antiprotease activity, rSLPI also exhibits intracellular activity in alveolar macrophages as 
it is here that it exerts an anti-inflammatory activity by binding to nuclear factor (NF)-
kappa B binding sites (Taggart et al., 2005). The encapsulation of rSLPI within liposomes 
that are specifically taken up AMs can therefore be regarded as a targeted carrier system. 
Liposome delivery to AMs has been successfully applied to the pulmonary delivery of 
cytotoxic antimicrobial agents such as amphotericin B (Brajtburg et al., 1990, Janknegt, 
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1996, Janknegt et al., 1992, Lopez-Berestein et al., 1983) and to enhance the efficacy of 
other antimicrobial agents targeting AMs such as ciprofloxacin (Conley et al., 1997, 
Wong et al., 2003).  
 
Early mast cell responses as well as late leukocyte activation following allergen-
bronchoprovocation significantly increase protease load in the airways (Fahy et al., 1995, 
Wenzel et al., 1988). This increase in proteolytic burden results in the inflammation and 
airway remodelling associated with asthma, as with other inflammatory lung diseases 
such as COPD, emphysema and cystic fibrosis. rSLPI provides a broad spectrum 
inhibitory activity against mast cell and leukocyte serine proteases and has previously 
been shown to prevent antigen-induced airway responses such as early and late phase 
responses, development of airway hyperresponsiveness, inflammatory cell influx, 
mucociliary dysfunction and airway inflammation in animal models of asthma (Barrios et 
al., 1998, Forteza et al., 2001, Wright et al., 1999). Studies have previously shown that 
rSLPI inhibits inflammatory cell recruitment (Murata et al., 2003, Sehnert et al., 2004, 
Wright et al., 1999) and so a reduction in inflammatory cell influx to the lungs was used 
in our study as a marker for free-rSLPI and DOPS-rSLPI activity in vivo.  
 
A significant reduction in eosinophil infiltration was observed for both free-rSLPI and 
DOPS-rSLPI treated animals. Indeed the eosinophil levels of those treated with free-
rSLPI and DOPS-rSLPI were the same as those seen in unchallenged (non-asthmatic) 
animals (Figure 6). Other studies examining the effect of prophylactic treatment with 
rSLPI on eosinophil influx have also demonstrated its ability to limit inflammatory cell 
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influx (Murata et al., 2003, Sehnert et al., 2004, Wright et al., 1999) but the controlled 
and targeted release properties exhibited by this liposome delivery system may allow 
DOPS-rSLPI to elicit its therapeutic effects for a longer period of time beyond the 24 
hours post-challenge tested in this study. 
 
 
 
 
 
 
Conclusions: 
Overall, the results of this study suggest that DOPS-rSLPI reduced the rate of clearance 
of rSLPI into the systemic circulation, increased lung residence-time and preferentially 
targeted alveolar macrophages, post-inhalation. This pharmacokinetic effect may offer a 
sustained pharmacodynamic activity over time. The observed in vitro-in vivo correlation 
for DOPS-rSLPI supports the use of Calu-3 monolayers for predicting the effect of 
excipients on protein transport in the lungs in vivo. In the broader context this work adds 
to knowledge in the field of liposomes for inhalation and particularly to their application 
for protein delivery and targeting. Prudent lipid selection can produce stable, protective 
delivery systems for inhalation with the ability to protect proteins, reduce clearance to the 
systemic circulation and potentially to target specific sites of action such as alveolar 
macrophages in vivo. 
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Figure Legends: 
 
Figure 1: Cumulative transport of free-rSLPI and rSLPI encapsulated in DOPS-rSLPI liposomes 
across a Calu-3 monolayer over 4 hours (n=4 ± S.D.) 
 
Figure 2: rSLPI plasma concentrations in single prophylacticly dosed guinea pigs. Plasma was 
collected 48 hours after a single 2.5mg rSLPI/kg dose by intratracheal instillation (free-rSLPI 
n=3; DOPS-rSLPI n=5; Control [DOPS-Empty or PBS] n= 6; ±S.D.) 
 
Figure 3: rSLPI concentration present in bronchoalveolar lavage fluid (BALF) of single 
prophylacticly dosed guinea pigs.  BALF was collected 48 hours after a single 2.5mg rSLPI/kg 
dose by intratracheal instillation. (free-rSLPI n=3; DOPS-rSLPI n=5; Control [DOPS-Empty or 
PBS] n=3; ±S.D.) 
 
Figure 4: a) rSLPI concentration in BALF cells taken from single prophylacticly dosed guinea 
pigs. Cell lysates were collected 48 hours after a single 2.5mg rSLPI/kg dose by intratracheal 
administration (i.t.). (free-rSLPI n=3; DOPS-rSLPI n=5; Control [DOPS-Empty or PBS] n=9; 
±S.D.) b) Uptake of neutral (DOPC) and anionic (DOPS) liposomes by differentiated THP-1 cells 
determined by high content analysis (HCA).  Cells were incubated for 2 hours with rhodamine-
labelled liposomes of different sizes, washed and analysed.  Data represented as means ± SEM (n 
= 9). 
 
Figure 5: Images taken of Leishman stained cells present in the BAL of guinea pigs after a single 
prophylactic dose of either i) control unchallenged animal, ii) Ova challenged only, iii) treated 
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with free-rSLPI (2.5mg rSLPI/kg) and Ova challenged or iv) treated with DOPS-rSLPI (2.5mg 
rSLPI/kg) and Ova challenged. 
 
Figure 6: Percentage cell type present in the airways expressed as a percentage of total cells 
present. A minimum of 500 cells was counted after cell differentiation using Leishman’s stain 
(Ova + DOPS-rSLPI n=5 ±S.D.; Ova + free-rSLPI n=3 ± S.D.; Ova challenged only n=3 ±S.D.; 
Control unchallenged animals n= 4±S.D.) 
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